InMed Pharmaceuticals (INM) has released an update.
InMed Pharmaceuticals has appointed Dr. Barry Greenberg, a renowned expert in Alzheimer’s disease, to its Scientific Advisory Board. Dr. Greenberg’s extensive experience will be crucial as the company advances its INM-901 drug candidate towards human trials. This move highlights InMed’s commitment to developing effective therapies for Alzheimer’s disease.
For further insights into INM stock, check out TipRanks’ Stock Analysis page.
